Listen to Taylor Jensen, PhD, Vice President and Head of Science discuss Labcorp Oncology: enabling access to precision medicine for all.

Hemodialysis (HD) patients spend more than 12 hours a week receiving lifesaving dialysis treatments at an out-patient HD unit.

Check out our presentation, where two specialists share insights to consider the inclusion of healthy volunteers (HVs) in first-in-human (FIH) oncology clinical trials with small molecules.

Follow along the journey of the sample as we show how robotics technology improves testing throughput and accuracy throughout our rigorous chain of specimen handling.

Labcorp's in-house snapClinical® DCT technology platform connects patients with virtual visits (e.g., eConsent, eDiaries, Televisist). Patients feel comfortable at home, work and school. snapClinical provides reminders and keeps participants engaged throughout the trial.

Cancer survival rates are often tied to a person's access to care.

Check our latest video to explore our snapClinical platform and Mobile Clinical Services and how it improved quality metrics, minimize enrollment burden on patients and sites and increase patient satisfaction.

Ensuring appropriate diverse demographic representation in clinical trials is imperative for all involved in bringing the miracle of new medicines to market - sponsors, CROs, sites, physicians and above all, the patients that are at the heart of any successful trial.

As studies have become more complex, we have expanded the role of a central lab to include key disciplines of specialty laboratory testing, including flow cytometry, targeted cell isolation, genomics and anatomic pathology and histology (APH).